H19 in Acute Lymphoblastic Leukemia.

NCT ID: NCT05943093

Last Updated: 2023-07-13

Basic Information

• Recruitment Status: UNKNOWN
• Total Enrollment: 96 participants
• Study Classification: OBSERVATIONAL
• Study Start Date: 2023-07-31
• Study Completion Date: 2025-08-31

Brief Summary

• Study the expression level of H19 gene in the samples from ALL patients by real-time PCR.
• Correlate the expression level of H19 gene with the clinical presentation and laboratory data of those patients.

Detailed Description

Acute lymphoblastic leukemia (ALL) is the most common cancer affecting children and adolescents (Zeng XL et al, 2023). ALL is a haematological malignancy characterized by the malignant clonal expansion of lymphoid hematopoietic precursors (Hong Z et al, 2021). It arises from B- or T-lineage lymphoid progenitors: B-cell-precursor ALL (B-ALL) and T-cell ALL (T-ALL) (Brady SW et al., 2022). Rrelapse in ALL is the fundamental cause of treatment failure in 15-20% of patients (Hulleman E et al, 2009). Therefore, the exploration of novel functional molecules that play a role in ALL pathogenesis could be effective therapeutic targets for this disease (Asadi M et al, 2023).

Long non-coding RNAs (lncRNAs) are non-protein coding transcripts longer than 200 nucleotides (Kopp F et al, 2018). H19 was the first lncRNA to be discovered and submitted for genomic imprinting (Yoshimura H et al, 2018). It has a role in embryogenesis and tumorigenesis (Yoshimura H et al, 2014). It also has an indispensable role in enhancing cell proliferation, differentiation, migration, invasion, and chemo resistance (Li Y et al, 2020). Recent evidence has shown that H19 is an oncogene and is overexpressed in breast, liver, endometrial, lung, cervical, and esophageal cancers (Asadi M et al, 2023). A similar pattern of H19 expression was observed in various types of leukemias, including chronic myeloid leukemia (CML) (Morlando M et al, 2015) and acute myeloid leukemia (AML) (Zhang Tj et al, 2018).

Conditions

Acute Lymphoid Leukemia

Study Design

• Observational Model Type: CASE_CONTROL
• Study Time Perspective: RETROSPECTIVE

Study Groups

ALL patients

No interventions assigned to this group

control group free from the disease

No interventions assigned to this group

Eligibility Criteria

Inclusion Criteria

• Newly diagnosed ALL patients.

Exclusion Criteria

• 1-Presence of other haematological disorders, history of other malignancies or relapsed ALL.

2-Patients under chemotherapy or radiotherapy.

• Minimum Eligible Age: 2 Months
• Maximum Eligible Age: 70 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

Assiut University

OTHER

Sponsor Role: lead

Responsible Party

Fatma Refaat Ibrahim Ismail

resident doctor

Responsibility Role: PRINCIPAL_INVESTIGATOR

Central Contacts

Fatma Refaat Ibrahim

Role: CONTACT

drfatmarefaat@gmail.com

01032073035

Hosney Badrawy Hamed, professor

Role: CONTACT

Badrawy@yahoo.com

Related Links

https://pubmed.ncbi.nlm.nih.gov/36680478/

Related Info

Other Identifiers

PCR in acute leukemia

Identifier Type: -

Identifier Source: org_study_id